@stemcellsciencenews.comThis Phase I, open-label, multicenter #ClincalStudy led by Dr. Paolo Strati enrolled adult patients with relapsed/refractory #lymphoma who had exhausted approved therapies.
The trial included dose escalation and expansion stages across multiple lymphoma subtypes.
